Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Total Liabilities
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has total liabilities worth CN¥273.93 Million CNY (≈ $40.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 688505 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
Total liabilities of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025. This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu TongLin Electric Co.Ltd.
SHE:301168
|
China | CN¥1.15 Billion |
|
Metro Healthcare Indonesia
JK:CARE
|
Indonesia | Rp1.17 Trillion |
|
Lotte Reit Co Ltd
KO:330590
|
Korea | ₩1.77 Trillion |
|
Cosonic Intelligent Tech Co Ltd
SHE:300793
|
China | CN¥1.41 Billion |
|
Sichuan Jiuyuan Yinhai Software Co Ltd
SHE:002777
|
China | CN¥738.71 Million |
|
Pakuwon Jati Tbk
JK:PWON
|
Indonesia | Rp10.08 Trillion |
|
Sichuan Yimikang Environmental Tech Co Ltd
SHE:300249
|
China | CN¥1.64 Billion |
|
Heilongjiang Transport Development Co Ltd
SHG:601188
|
China | CN¥979.89 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shanghai Fudan-Zhangjiang Bio-Pharmaceut balance sheet assets.
Liquidity & Leverage Metrics
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual total liabilities of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥273.93 Million ≈ $40.09 Million |
-2.59% |
| 2024-12-31 | CN¥281.23 Million ≈ $41.15 Million |
-45.72% |
| 2023-12-31 | CN¥518.12 Million ≈ $75.82 Million |
-28.34% |
| 2022-12-31 | CN¥722.99 Million ≈ $105.80 Million |
+22.21% |
| 2021-12-31 | CN¥591.58 Million ≈ $86.57 Million |
+20.19% |
| 2020-12-31 | CN¥492.21 Million ≈ $72.03 Million |
-22.08% |
| 2019-12-31 | CN¥631.68 Million ≈ $92.43 Million |
+35.53% |
| 2018-12-31 | CN¥466.08 Million ≈ $68.20 Million |
+84.47% |
| 2017-12-31 | CN¥252.65 Million ≈ $36.97 Million |
+2.00% |
| 2016-12-31 | CN¥247.70 Million ≈ $36.25 Million |
-2.64% |
| 2015-12-31 | CN¥254.43 Million ≈ $37.23 Million |
+71.84% |
| 2014-12-31 | CN¥148.06 Million ≈ $21.67 Million |
-19.22% |
| 2013-12-31 | CN¥183.29 Million ≈ $26.82 Million |
-33.87% |
| 2012-12-31 | CN¥277.18 Million ≈ $40.56 Million |
+75.64% |
| 2011-12-31 | CN¥157.81 Million ≈ $23.09 Million |
+16.51% |
| 2010-12-31 | CN¥135.45 Million ≈ $19.82 Million |
+3.82% |
| 2009-12-31 | CN¥130.46 Million ≈ $19.09 Million |
+58.00% |
| 2008-12-31 | CN¥82.57 Million ≈ $12.08 Million |
+39.15% |
| 2007-12-31 | CN¥59.34 Million ≈ $8.68 Million |
+36.97% |
| 2006-12-31 | CN¥43.32 Million ≈ $6.34 Million |
+125.88% |
| 2005-12-31 | CN¥19.18 Million ≈ $2.81 Million |
-- |
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more